Loading…
Phytag Labs was cited for marketing GlucoType2 as an unapproved new drug rather than a dietary supplement, making disease claims including blood sugar control, diabetes treatment, and reduction of inflammation, cholesterol, and nerve pain without FDA approval. The company violated the Federal Food, Drug, and Cosmetic Act by promoting the product through their website and Amazon storefront with claims that established it as a drug intended to cure, mitigate, treat, or prevent disease. The FDA and Federal Trade Commission jointly reviewed the company's marketing materials in August 2021 and determined the product could not be legally sold as presented.